文献速递胸部肿瘤乳腺癌消化系统肿瘤

靶向HER2的德曲妥珠单抗:多实体瘤剂量扩展I期研究

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
PubMed 文献 · Cancer Discov · 2020-03-25

这项I期剂量扩展研究评估了德曲妥珠单抗(T-DXd)在60例经治、HER2表达(IHC≥1+)的非乳腺癌/非胃癌或HER2突变实体瘤患者中的安全性与活性。确认客观缓解率(ORR)为28.3%(17/60),中位无进展生存期(PFS)为7.2个月(95%CI 4.8-11.1)。在HER2突变非小细胞肺癌(NSCLC)中,ORR达72.7%(8/11),中位PFS为11.3个月(95%CI 8.1-14.3)。

要点

  • T-DXd在经治HER2表达或突变实体瘤中显示活性,确认ORR为28.3%。
  • HER2突变NSCLC亚组ORR达72.7%,中位PFS为11.3个月。
  • 常见治疗中出现不良事件(>50%)为恶心、食欲下降和呕吐,需警惕间质性肺病。

核心结论

  • T-DXd在经治HER2表达或突变实体瘤中显示出有前景的抗肿瘤活性,尤其在HER2突变NSCLC中。
  • 安全性总体可接受,但间质性肺病可能严重,需及时监测和干预。

研究设计与样本

  • I期剂量扩展研究(NCT02564900),纳入60例经治、HER2表达(IHC≥1+)的非乳腺癌/非胃癌或HER2突变实体瘤患者。

主要发现

  • 确认ORR为28.3%(17/60),中位PFS为7.2个月(95%CI 4.8-11.1)。
  • HER2突变NSCLC亚组ORR为72.7%(8/11),中位PFS为11.3个月(95%CI 8.1-14.3)。
  • 在六种肿瘤类型中观察到确认缓解,包括HER2表达NSCLC、结直肠癌、唾液腺癌、胆道癌、子宫内膜癌以及HER2突变NSCLC和乳腺癌。
  • 最常见(>50%)治疗中出现不良事件为恶心、食欲下降和呕吐;两例药物相关不良事件与致命结局相关。

关键数值与推荐

  • HER2表达定义为IHC≥1+。
  • 确认ORR为28.3%(17/60),中位PFS为7.2个月(95%CI 4.8-11.1)。
  • HER2突变NSCLC中ORR为72.7%(8/11),中位PFS为11.3个月(95%CI 8.1-14.3)。

临床怎么用

  • 对于经治HER2表达或突变实体瘤患者,T-DXd可作为潜在治疗选择,尤其HER2突变NSCLC。
  • 治疗期间需监测间质性肺病,及时干预。

局限性

  • 研究为I期剂量扩展研究,样本量较小(60例),结果需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers. We assessed the safety/tolerability and activity of the novel HER2-targeted antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in 60 patients with pretreated, HER2-expressing (IHC ≥ 1+), non-breast/non-gastric or HER2-mutant solid tumors from a phase I trial (NCT02564900). Most common (>50%) treatment-emergent adverse events (TEAE) were nausea, decreased appetite, and vomiting. Two drug-related TEAEs were associated with fatal outcomes. The confirmed objective response rate (ORR) was 28.3% (17/60). Median progression-free survival (PFS) was 7.2 [95% confidence interval (CI), 4.8-11.1] months. In HER2-mutant non-small cell lung cancer (NSCLC), ORR was 72.7% (8/11), and median PFS was 11.3 (95% CI, 8.1-14.3) months. Confirmed responses were observed in six tumor types, including HER2-expressing NSCLC, colorectal cancer, salivary gland cancer, biliary tract cancer, endometrial cancer, and HER2-mutant NSCLC and breast cancer. Results suggest T-DXd holds promise for HER2-expressing/mutant solid tumors. SIGNIFICANCE: T-DXd demonstrated promising activity in a heterogeneous patient population with heavily pretreated HER2-expressing or HER2-mutant solid tumors, especially HER2-mutant NSCLC. The safety profile was generally acceptable. Interstitial lung disease can be severe and requires prompt monitoring and intervention. Further research of T-DXd is warranted to address these unmet medical needs.See related commentary by Rolfo and Russo, p. 643.This article is highlighted in the In This Issue feature, p. 627.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Tsurutani J, Iwata H, Krop I, et al. Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. Cancer Discov. 2020. PMID: 32213540. doi:10.1158/2159-8290.CD-19-1014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。